← All trials
NCT06902350
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 21, 2025
- Primary completion
- Apr 30, 2029
- Completion date
- Apr 30, 2029
- First posted
- Mar 30, 2025
- Last posted
- May 25, 2025
- Enrollment
- 102
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Chipscreen Biosciences, Ltd.Lead sponsor
- Jilin Provincial Tumor HospitalOfficial
- Capital Medical UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.